Last 12 months
Inside the activity.
10 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 4 | 0 |
| Dec 2025 | 2 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 4 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2022 Filed Jul 5, 2022 20:30 UTC |
TRAVERSA SERGIODirector · Chief Executive Officer
|
SaleCommon Stock | 839 | $18.48 | $15,504.72 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · nonDerivative · entry 5 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,690 F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F5 · price: Sales prices range from $18.47 to $18.53 per share, inclusive. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:30 UTC |
TRAVERSA SERGIODirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 13,755 | $16.00 | $220,080.00 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · nonDerivative · entry 4 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:30 UTC |
TRAVERSA SERGIODirector · Chief Executive Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 16,012 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · derivative · entry 8 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,755 Underlying: Common Stock · 16,012 shares Expires 2022-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022. F8 · derivative.exercise_date: The options were granted on July 10, 2012 (the "Grant Date"). 25% of the options vested upon the Grant Date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:30 UTC |
TRAVERSA SERGIODirector · Chief Executive Officer
|
SaleCommon Stock | 10,698 | $19.01 | $203,368.98 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · nonDerivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,774 F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $19.00 to $19.15 per share, inclusive. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:30 UTC |
TRAVERSA SERGIODirector · Chief Executive Officer
|
SaleCommon Stock | 5,314 | $19.37 | $102,932.18 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,472 F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $19.20 to $19.51 per share, inclusive. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:30 UTC |
TRAVERSA SERGIODirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 16,012 | $16.00 | $256,192.00 |
DisclosureSEC source: 0001213900-22-037231 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022. Read SEC document |
| May 25, 2022 Filed May 26, 2022 22:38 UTC |
CASAMENTO CHARLES JDirector
|
GrantStock Option (right to buy) · Derivative | 91,235 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029832 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 91,235 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022. Read SEC document |
| May 25, 2022 Filed May 26, 2022 18:43 UTC |
Kelly Paul EdwardDirector
|
GrantStock Option (right to buy) · Derivative | 182,470 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029838 · ownership.xml · derivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 182,470 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022. Read SEC document |
| May 25, 2022 Filed May 26, 2022 18:42 UTC |
Shenouda MagedChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029837 · ownership.xml · derivative · entry 2 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F3 · derivative.exercise_date: 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of dextromethadone (REL-1017) in major depressive disorder ("MDD") complete enrollment, as defined in the respective Trial's protocol, with 364 patients per Trial with the last patient in for each trial to be enrolled by December 31, 2022. The remaining 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of REL-1017 in MDD report top-line data by December 31, 2023, and meet or exceed their primary and key secondary endpoints as defined in in the respective Trial's protocol. Read SEC document |
| May 25, 2022 Filed May 26, 2022 18:42 UTC |
Shenouda MagedChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 295,211 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029837 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,729 Underlying: Common Stock · 295,211 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022. Read SEC document |
| May 25, 2022 Filed May 26, 2022 22:39 UTC |
Ence ChuckCA and Compliance Officer
|
GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029833 · ownership.xml · derivative · entry 2 Ence Chuck · CIK 0001697779 · CA and Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F3 · derivative.exercise_date: 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of dextromethadone (REL-1017) in major depressive disorder ("MDD") complete enrollment, as defined in the respective Trial's protocol, with 364 patients per Trial with the last patient in for each trial to be enrolled by December 31, 2022. The remaining 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of REL-1017 in MDD report top-line data by December 31, 2023, and meet or exceed their primary and key secondary endpoints as defined in in the respective Trial's protocol. Read SEC document |
| May 25, 2022 Filed May 26, 2022 22:39 UTC |
Ence ChuckCA and Compliance Officer
|
GrantStock Option (right to buy) · Derivative | 295,404 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029833 · ownership.xml · derivative · entry 1 Ence Chuck · CIK 0001697779 · CA and Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,236 Underlying: Common Stock · 295,404 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022. Read SEC document |
| May 25, 2022 Filed May 26, 2022 22:45 UTC |
TRAVERSA SERGIODirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029839 · ownership.xml · derivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F3 · derivative.exercise_date: 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of dextromethadone (REL-1017) in major depressive disorder ("MDD") complete enrollment, as defined in the respective Trial's protocol, with 364 patients per Trial with the last patient in for each trial to be enrolled by December 31, 2022. The remaining 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of REL-1017 in MDD report top-line data by December 31, 2023, and meet or exceed their primary and key secondary endpoints as defined in in the respective Trial's protocol. Read SEC document |
| May 25, 2022 Filed May 26, 2022 22:45 UTC |
TRAVERSA SERGIODirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 651,821 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029839 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143,994 Underlying: Common Stock · 651,821 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022. Read SEC document |
| May 25, 2022 Filed May 26, 2022 22:41 UTC |
GLASSPOOL JOHNDirector
|
GrantStock Option (right to buy) · Derivative | 91,235 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029835 · ownership.xml · derivative · entry 1 GLASSPOOL JOHN · CIK 0001644079 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 91,235 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022. Read SEC document |
| May 25, 2022 Filed May 26, 2022 22:41 UTC |
SCHMIDT ERIC THOMASDirector
|
GrantStock Option (right to buy) · Derivative | 91,235 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029834 · ownership.xml · derivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 91,235 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 17:34 UTC |
Kelly Paul EdwardDirector
|
Exercise / conversionOptions to purchase common stock · Derivative | 10,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-22-018223 · ownership.xml · derivative · entry 3 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 10,000 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 17:34 UTC |
Kelly Paul EdwardDirector
|
SaleCommon Stock | 10,000 | $30.04 | $300,395.00 |
DisclosureSEC source: 0001213900-22-018223 · ownership.xml · nonDerivative · entry 2 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,295 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $30.00 to $30.20 per share, inclusive. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 17:34 UTC |
Kelly Paul EdwardDirector
|
Exercise / conversionCommon Stock | 10,000 | $3.24 | $32,400.00 |
DisclosureSEC source: 0001213900-22-018223 · ownership.xml · nonDerivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC |
CASAMENTO CHARLES JDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 19,800 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · derivative · entry 8 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,511 Underlying: Common Stock · 19,800 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC |
CASAMENTO CHARLES JDirector
|
SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 7 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC |
CASAMENTO CHARLES JDirector
|
SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 6 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC |
CASAMENTO CHARLES JDirector
|
SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 5 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,600 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC |
CASAMENTO CHARLES JDirector
|
SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 4 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,900 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC |
CASAMENTO CHARLES JDirector
|
SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 3 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC |
CASAMENTO CHARLES JDirector
|
SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC |
CASAMENTO CHARLES JDirector
|
Exercise / conversionCommon Stock | 19,800 | $3.24 | $64,152.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:01 UTC |
Kelly Paul EdwardDirector
|
Exercise / conversionOptions to purchase common stock · Derivative | 20,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-22-000761 · ownership.xml · derivative · entry 2 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 20,000 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:01 UTC |
Kelly Paul EdwardDirector
|
Exercise / conversionCommon Stock | 20,000 | $3.24 | $64,800.00 |
DisclosureSEC source: 0001213900-22-000761 · ownership.xml · nonDerivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2021 Filed Dec 22, 2021 02:30 UTC |
CASAMENTO CHARLES JDirector
|
GrantStock Option (right to buy) · Derivative | 58,765 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-21-066819 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,765 Underlying: Common Stock · 58,765 shares Expires 2031-12-17 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 21:30 UTC |
Shenouda MagedChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 227,518 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-21-066822 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,518 Underlying: Common Stock · 227,518 shares Expires 2031-12-17 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 21:30 UTC |
Kelly Paul EdwardDirector
|
GrantStock Option (right to buy) · Derivative | 117,530 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-21-066821 · ownership.xml · derivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,530 Underlying: Common Stock · 117,530 shares Expires 2031-12-17 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022. Read SEC document |
| December 17, 2021 Filed Dec 22, 2021 02:31 UTC |
TRAVERSA SERGIODirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 492,173 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-21-066825 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,173 Underlying: Common Stock · 492,173 shares Expires 2031-12-17 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022. Read SEC document |
| December 17, 2021 Filed Dec 22, 2021 02:31 UTC |
GLASSPOOL JOHNDirector
|
GrantStock Option (right to buy) · Derivative | 58,765 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-21-066824 · ownership.xml · derivative · entry 1 GLASSPOOL JOHN · CIK 0001644079 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,765 Underlying: Common Stock · 58,765 shares Expires 2031-12-17 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022. Read SEC document |
| December 17, 2021 Filed Dec 22, 2021 02:31 UTC |
SCHMIDT ERIC THOMASDirector
|
GrantStock Option (right to buy) · Derivative | 58,765 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-21-066823 · ownership.xml · derivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,765 Underlying: Common Stock · 58,765 shares Expires 2031-12-17 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022. Read SEC document |
| December 17, 2021 Filed Dec 22, 2021 02:30 UTC |
Ence ChuckCAO and Compliance Officer
|
GrantStock Option (right to buy) · Derivative | 226,832 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-21-066820 · ownership.xml · derivative · entry 1 Ence Chuck · CIK 0001697779 · CAO and Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,832 Underlying: Common Stock · 226,832 shares Expires 2031-12-17 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022. Read SEC document |
| December 03, 2021 Filed Feb 2, 2023 22:00 UTC |
CASAMENTO CHARLES JDirector
|
GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-007436 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The La Jolla Lenox Trust Disclosed balance after: 10,000 F1 · shares: On December 3, 2021, the Reporting Person transferred 10,000 shares of the Issuer's common stock to a family trust of which the Trustee is someone other than the Reporting Person. The Reporting Person and members of his immediate family are the sole beneficiaries of the trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the filing of this report is not an admission that The Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 03, 2021 Filed Feb 2, 2023 22:00 UTC |
CASAMENTO CHARLES JDirector
|
GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-007436 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC |
CASAMENTO CHARLES JDirector
|
Exercise / conversionOptions to purchase common stock · Derivative | 1,900 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-049820 · ownership.xml · derivative · entry 5 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,311 Underlying: Common Stock · 1,900 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable F2 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC |
CASAMENTO CHARLES JDirector
|
SaleCommon Stock | 1,400 | $29.00 | $40,600.00 |
DisclosureSEC source: 0001213900-21-049820 · ownership.xml · nonDerivative · entry 4 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC |
CASAMENTO CHARLES JDirector
|
SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-21-049820 · ownership.xml · nonDerivative · entry 3 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,400 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC |
CASAMENTO CHARLES JDirector
|
SaleCommon Stock | 1,900 | $29.00 | $55,100.00 |
DisclosureSEC source: 0001213900-21-049820 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,700 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC |
CASAMENTO CHARLES JDirector
|
Exercise / conversionCommon Stock | 10,000 | $4.60 | $46,000.00 |
DisclosureSEC source: 0001213900-21-049820 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:00 UTC |
CASAMENTO CHARLES JDirector
|
Exercise / conversionOptions to purchase common stock · Derivative | 10,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001213900-21-043907 · ownership.xml · derivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,500 Underlying: Common Stock · 10,000 shares Expires 2028-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:00 UTC |
CASAMENTO CHARLES JDirector
|
Exercise / conversionCommon Stock | 10,000 | $4.60 | $46,000.00 |
DisclosureSEC source: 0001213900-21-043907 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 21:00 UTC |
CASAMENTO CHARLES JDirector
|
SaleCommon Stock | 1,164 | $32.49 | $37,816.38 |
DisclosureSEC source: 0001213900-21-037273 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,700 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $32.32 to $32.93 per share, inclusive Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 21:00 UTC |
CASAMENTO CHARLES JDirector
|
SaleCommon Stock | 2,136 | $31.03 | $66,271.96 |
DisclosureSEC source: 0001213900-21-037273 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,854 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $30.66 to $31.60 per share, inclusive. Read SEC document |
| July 08, 2021 Filed Feb 2, 2023 17:00 UTC |
Kelly Paul EdwardDirector
|
GiftStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-23-007438 · ownership.xml · derivative · entry 4 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,000 Underlying: Common Stock · 18,000 shares Expires 2031-01-07 F1 · kind: Represents a bona fide gift of stock options to family members and a family trust. An independent trustee is trustee of the trust. F5 · derivative.exercise_date: The options were granted on January 7, 2021. 6.25% of the options vest each quarter from the date of grant. Read SEC document |
| July 08, 2021 Filed Feb 2, 2023 17:00 UTC |
Kelly Paul EdwardDirector
|
GiftStock Option (right to buy) · Derivative | 56,000 | $0.00 Strike: $43.47 | $0.00 |
DisclosureSEC source: 0001213900-23-007438 · ownership.xml · derivative · entry 3 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Underlying: Common Stock · 56,000 shares Expires 2029-12-19 F1 · kind: Represents a bona fide gift of stock options to family members and a family trust. An independent trustee is trustee of the trust. F4 · derivative.exercise_date: The options were granted on December 19, 2019. 6.25% of the options vest each quarter from the date of grant. Read SEC document |
| July 08, 2021 Filed Feb 2, 2023 17:00 UTC |
Kelly Paul EdwardDirector
|
GiftStock Option (right to buy) · Derivative | 19,600 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001213900-23-007438 · ownership.xml · derivative · entry 2 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,400 Underlying: Common Stock · 19,600 shares Expires 2029-07-29 F1 · kind: Represents a bona fide gift of stock options to family members and a family trust. An independent trustee is trustee of the trust. F3 · derivative.exercise_date: The options were granted on July 29, 2019. 6.25% of the options vest each quarter from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.